Journal
FRONTIERS IN CELLULAR NEUROSCIENCE
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fncel.2018.00435
Keywords
Alzheimer's disease; amyloid precursor protein; amyloid beta peptide; APP-CTF; C99
Categories
Funding
- ANR VIDALZ [ANR-15-CE18-0002]
- Labex DISTALZ (Development of Innovative Strategies for a Transdisciplinary Approach to Alzheimer's Disease)
- Lille 2 University
Ask authors/readers for more resources
A beta peptides, the major components of Alzheimer's disease (AD) amyloid deposits, are released following sequential cleavages by secretases of its precursor named the amyloid precursor protein (APP). In addition to secretases, degradation pathways, in particular the endosomal/lysosomal and proteasomal systems have been reported to contribute to APP processing. However, the respective role of each of these pathways toward APP metabolism remains to be established. To address this, we used HEK 293 cells and primary neurons expressing full-length wild type APP or the beta-secretase-derived C99 fragment (beta-CTF) in which degradation pathways were selectively blocked using pharmacological drugs. APP metabolites, including carboxy-terminal fragments (CTFs), soluble APP (sAPP) and A beta peptides were studied. In this report, we show that APP-CTFs produced from endogenous or overexpressed full-length APP are mainly processed by gamma-secretase and the endosomal/lysosomal pathway, while in sharp contrast, overexpressed C99 is mainly degraded by the proteasome and to a lesser extent by gamma-secretase.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available